Payment overview · 2025
General Payments
$114.00
7 reported records · 6 companies
Healthcare provider profile · identity verified
Amy Marie Turner, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CLINTON, KY · NPI 1639680846
Verified facts
What the public records show
CMS Open Payments records show Amy Marie Turner, APRN received $114.00 in general payments during 2025 across 7 reported records.
Axsome Therapeutics, Inc. accounted for 27.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.00 | 27.2% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.16 | 16.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.17 | 15.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.82 | 14.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.55 | 12.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.30 | 12.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $114.00 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $31.00 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
74 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 412 | 89 |
| Omeprazole | Omeprazole | 337 | 74 |
| Lisinopril | Lisinopril | 275 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 257 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 252 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 245 | 58 |
| Gabapentin | Gabapentin | 232 | 49 |
| Furosemide | Furosemide | 230 | 67 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 218 | 48 |
| Metformin Hcl | Metformin Hcl | 207 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 184 | 40 |
| Buspirone Hcl | Buspirone Hcl | 183 | 41 |
| Losartan Potassium | Losartan Potassium | 182 | 46 |
| Meloxicam | Meloxicam | 158 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 158 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 143 | 33 |
| Montelukast Sodium | Montelukast Sodium | 141 | 25 |
| Prednisone | Prednisone | 141 | 95 |
| Jardiance | Empagliflozin | 135 | 26 |
| Potassium Chloride | Potassium Chloride | 134 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 132 | 32 |
| Sertraline Hcl | Sertraline Hcl | 131 | 31 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 130 | 33 |
| Clonazepam | Clonazepam | 129 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 32 |
| Simvastatin | Simvastatin | 107 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 105 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 104 | 28 |
| Eliquis | Apixaban | 103 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 23 |
| Trazodone Hcl | Trazodone Hcl | 102 | 24 |
| Ozempic | Semaglutide | 101 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 99 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 98 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 23 |
| Cefdinir | Cefdinir | 94 | 71 |
| Alprazolam | Alprazolam | 88 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 88 | 61 |
| Ondansetron Odt | Ondansetron | 88 | 44 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 85 | 51 |
| Pregabalin | Pregabalin | 83 | 17 |
| Baclofen | Baclofen | 82 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 77 | 14 |
| Linzess | Linaclotide | 74 | 14 |
| Fluconazole | Fluconazole | 71 | 35 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 70 | 54 |
| Azithromycin | Azithromycin | 70 | 49 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 15 |
| Carvedilol | Carvedilol | 66 | 16 |
| Temazepam | Temazepam | 63 | 11 |
| Ezetimibe | Ezetimibe | 62 | 20 |
| Meclizine Hcl | Meclizine Hcl | 62 | 27 |
| Nifedipine Er | Nifedipine | 62 | 13 |
| Januvia | Sitagliptin Phosphate | 61 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | suppressed |
| Bumetanide | Bumetanide | 60 | 17 |
| Allopurinol | Allopurinol | 59 | 17 |
| Trulicity | Dulaglutide | 57 | suppressed |
| Ibuprofen | Ibuprofen | 55 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | suppressed |
| Repatha Sureclick | Evolocumab | 53 | suppressed |
| Diazepam | Diazepam | 52 | 13 |
| Glipizide | Glipizide | 52 | 12 |
| Mirtazapine | Mirtazapine | 52 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | 11 |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Nystatin | Nystatin | 49 | 28 |
| Famotidine | Famotidine | 48 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 11 |
| Tramadol Hcl | Tramadol Hcl | 45 | 19 |
| Glimepiride | Glimepiride | 43 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 13 |
| Estradiol | Estradiol | 38 | suppressed |
| Olanzapine | Olanzapine | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 26 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Amoxicillin | Amoxicillin | 35 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 25 |
| Topiramate | Topiramate | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 25 |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 33 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Lorazepam | Lorazepam | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 12 |
| Celecoxib | Celecoxib | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 27 | 22 |
| Atenolol | Atenolol | 26 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 13 |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 18 |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Victoza 3-Pak | Liraglutide | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Methimazole | Methimazole | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | 11 |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $114.00 · 7 records | Axsome Therapeutics, Inc. | Auvelity, BREZTRI, CAPLYTA, MINIMED 780G, REXULTI, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error